Effects of dextromethorphan as add‐on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo‐controlled, double‐blinded, multiple crossover, single‐dose clinical trial

Autor: Eckhard Lammert, Annelie Fischer, Tim Heise, Alin Stirban, Silke Otter, F. Sievers, Freimut Schliess, Jan Marquard, Stephan Wnendt, Thomas Meissner, Alena Welters
Rok vydání: 2015
Předmět:
Blood Glucose
Male
0301 basic medicine
insulin secretion
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Pharmacology
Dextromethorphan
DPP‐IV inhibitor
0302 clinical medicine
Endocrinology
Insulin
Glucose tolerance test
Cross-Over Studies
medicine.diagnostic_test
Area under the curve
Middle Aged
Sitagliptin
Drug Therapy
Combination
type 2 diabetes
NMDA
antidiabetic drug
medicine.drug
medicine.medical_specialty
030209 endocrinology & metabolism
Placebo
Sitagliptin Phosphate
03 medical and health sciences
Double-Blind Method
Internal medicine
Research Letter
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Aged
Dipeptidyl-Peptidase IV Inhibitors
Dose-Response Relationship
Drug
business.industry
Glucose Tolerance Test
Crossover study
Research Letters
Hypoglycemia
030104 developmental biology
Diabetes Mellitus
Type 2
business
Excitatory Amino Acid Antagonists
Zdroj: Diabetes, obesity and metabolism, 18(1):100-103
Diabetes, Obesity & Metabolism
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.12576
Popis: In this clinical trial, we investigated the blood glucose (BG)‐lowering effects of 30, 60 and 90 mg dextromethorphan (DXM) as well as 100 mg sitagliptin alone versus combinations of DXM and sitagliptin during an oral glucose tolerance test (OGTT) in 20 men with T2DM. The combination of 60 mg DXM plus 100 mg sitagliptin was observed to have the strongest effect in the OGTT. It lowered maximum BG concentrations and increased the baseline‐adjusted area under the curve for serum insulin concentrations in the first 30 min of the OGTT (mean ± standard deviation 240 ± 47 mg/dl and 8.1 ± 6.1 mU/l/h, respectively) to a significantly larger extent than did 100 mg sitagliptin alone (254 ± 50 mg/dl and 5.8 ± 2.5 mU/l/h, respectively; p < 0.05) and placebo (272 ± 49 mg/dl and 3.9 ± 3.0 mU/l/h, respectively; p < 0.001). All study drugs were well tolerated, alone and in combination, without serious adverse events or hypoglycaemia. Long‐term clinical trials are now warranted to investigate the potential of the combination of 30 or 60 mg DXM and dipeptidyl peptidase‐4 inhibitors in the treatment of individuals with T2DM, in particular as preclinical studies have identified the β‐cell protective properties of DXM.
Databáze: OpenAIRE
Externí odkaz: